Earnings summaries and quarterly performance for ALX ONCOLOGY HOLDINGS.
Executive leadership at ALX ONCOLOGY HOLDINGS.
Board of directors at ALX ONCOLOGY HOLDINGS.
Research analysts who have asked questions during ALX ONCOLOGY HOLDINGS earnings calls.
Allison Bratzel
Piper Sandler Companies
1 question for ALXO
Also covers: ABCL, AKBA, ARDX +5 more
LW
Li Wang Watsek
Cantor Fitzgerald
1 question for ALXO
Also covers: AFMD, ARVN, ASND +7 more
RS
Roger Song
Jefferies
1 question for ALXO
Also covers: AADI, AKBA, ALT +13 more
Sam Slutsky
LifeSci Capital, LLC
1 question for ALXO
Also covers: KYMR, PVLA, RAIN +1 more
TL
Ting Liu
UBS Group
1 question for ALXO
Also covers: ABOS
YH
Yu He (Arthur)
H.C. Wainwright & Co., LLC
1 question for ALXO
Also covers: AUPH, NKTR
Recent press releases and 8-K filings for ALXO.
ALX Oncology Announces Pricing of Underwritten Offering
ALXO
New Projects/Investments
- ALX Oncology Holdings Inc. announced the pricing of an underwritten offering of 76,979,112 shares of common stock at $1.57 per share and 18,574,120 pre-funded warrants at $1.569 per pre-funded warrant.
- The offering is expected to generate approximately $150 million in gross proceeds before deductions and is anticipated to close on or about February 2, 2026.
- The net proceeds from the offering will be used to fund the continued clinical development of evorpacept and its ALX2004 program, related clinical trials, working capital, and other general corporate purposes.
- The financing is being led by new investors RA Capital Management and TCGX, with participation from additional new and existing investors.
8 days ago
ALX Oncology Announces Pricing of Underwritten Offering
ALXO
New Projects/Investments
- ALX Oncology Holdings Inc. (ALXO) announced the pricing of an underwritten offering, selling 76,979,112 shares of common stock at $1.57 per share and 18,574,120 pre-funded warrants at $1.569 per pre-funded warrant.
- The offering is expected to generate approximately $150 million in gross proceeds for ALX Oncology.
- The net proceeds are anticipated to fund the continued clinical development of evorpacept and its ALX2004 program, as well as for working capital and general corporate purposes.
- The financing is led by new investors RA Capital Management and TCGX, with the offering expected to close on or about February 2, 2026.
8 days ago
ALX Oncology Announces New Clinical Data and Preliminary Cash Position
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology Holdings Inc. announced new data from a Phase 1b/2 clinical trial evaluating its investigational CD47-inhibitor evorpacept in combination with ZIIHERA (zanidatamab-hrii) in heavily pretreated patients with metastatic breast cancer.
- An exploratory analysis from the trial indicated that CD47 expression is predictive of evorpacept activity in patients with confirmed HER2-positive metastatic breast cancer, reinforcing previous findings from the ASPEN-06 trial.
- Primary results from the trial, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), demonstrated a 56% confirmed objective response rate (cORR) and a median progression-free survival (mPFS) of 7.4 months in nine HER2-positive breast cancer patients.
- The company also disclosed preliminary unaudited estimates of approximately $48.3 million in cash and cash equivalents and short-term and long-term investments as of December 31, 2025.
8 days ago
ALX Oncology Announces New Data on Evorpacept in HER2-Positive Breast Cancer
ALXO
New Projects/Investments
- ALX Oncology announced new exploratory data from a Phase 1b/2 clinical trial evaluating its CD47-inhibitor evorpacept in combination with zanidatamab-hrii for heavily pretreated patients with metastatic breast cancer (mBC).
- The findings indicate that CD47 expression is predictive of evorpacept activity among patients with confirmed HER2-positive mBC, reinforcing results from the ASPEN-06 trial and supporting the ongoing ASPEN-09-Breast Phase 2 trial.
- Primary results from the trial, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), previously showed a 56% (5/9) confirmed objective response rate (cORR) and a median progression-free survival (mPFS) of 7.4 months in nine patients with centrally confirmed HER2-positive breast cancer.
8 days ago
ALX Oncology Provides Update on Clinical-Stage Programs
ALXO
New Projects/Investments
- ALX Oncology is advancing two clinical-stage programs: Evorpacept, a CD47 inhibitor, and ALX 2004, an EGFR-targeted ADC, both designed with differentiated mechanisms.
- Evorpacept is currently in an 80-patient single-arm trial for HER2-positive breast cancer, with interim data predicted in Q3 2026.
- The company's internally developed ALX 2004 is in Phase 1, having cleared the first two dose cohorts and currently enrolling patients at 4 mg/kg, with data on its safety profile anticipated in the first half of 2026.
- ALX Oncology aims to have both Evorpacept and ALX 2004 on registrational paths by the end of 2026.
Jan 15, 2026, 8:00 PM
ALX Oncology Advances Cancer Treatments with Key 2026 Catalysts
ALXO
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Evorpacept, ALX Oncology's leading CD47 program, demonstrated strong activity in multiple combinations, including a 65% ORR in 2L gastric cancer (vs 26% control) for HER2+ CD47-high patients and a 56% ORR in HER2+ breast cancer patients with prior Enhertu. The company anticipates an interim analysis for the ASPEN-Breast trial in Q3 2026, targeting a $2-4 billion market opportunity in CD47-high, HER2+ 2L+ breast cancer.
- The highly differentiated EGFR ADC, ALX2004, is currently in Phase 1 dose escalation for EGFR-expressing solid tumors, with initial safety data expected in 1H 2026. Preclinical data supports its differentiated safety profile and superior activity compared to deruxtecan comparators in bystander effect models.
- ALX Oncology projects a catalyst-rich 2026, driven by key milestones such as the ALX2004 initial safety data and ASPEN-Breast data, with a projected cash runway extending into Q1 2027.
Jan 15, 2026, 8:00 PM
ALX Oncology Highlights Advancements in Cancer Treatments and Upcoming 2026 Milestones
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology is advancing two novel cancer treatments: Evorpacept, a CD47 program with an inactive Fc design, and ALX2004, a differentiated EGFR ADC.
- The company anticipates two key inflection points in 2026: interim data for Evorpacept in breast cancer in Q3 2026 and initial safety data for ALX2004 in EGFR-expressing solid tumors in 1H 2026.
- Evorpacept has demonstrated consistent tolerability and robust clinical activity, including a 61% reduction in the risk of disease progression or death for patients with CD47-High expression in the ASPEN-06 gastric study.
- ALX2004, currently in Phase 1 dose escalation, has shown potent anti-tumor activity in preclinical models and a differentiated safety profile, supporting its clinical development.
- ALX Oncology has a projected cash runway into Q1 2027, with $67 million in cash, cash equivalents, and investments as of September 30, 2025.
Jan 15, 2026, 12:00 PM
ALX Oncology Provides Updates on Evorpacept and ALX 2004 Programs
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology's lead program, evorpacept, a CD47 blocker, demonstrated a 65% response rate in patients with high CD47 expression in a Phase 2 gastric cancer study, compared to 26% in the control arm.
- Following FDA feedback, ALX Oncology is shifting its focus for evorpacept development to HER2-positive breast cancer, with interim data from a new Phase 2 study anticipated in Q3 2026.
- The company's new EGFR-targeted ADC, ALX 2004, has entered Phase 1 clinical trials, with initial safety data expected in the first half of 2026 and efficacy data to follow.
- ALX Oncology projects its cash runway to extend through Q1 2027.
Dec 3, 2025, 2:30 PM
ALX Oncology Provides Updates on Clinical Programs and Financial Runway
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology's lead program, evorpacept, a CD47 blocker, is being advanced in combination with anti-cancer antibodies, with a strategic shift away from checkpoint inhibitors.
- In a Phase 2 gastric cancer study, evorpacept demonstrated a 41% Overall Response Rate (ORR) versus 26% in the control arm, with patients having high CD47 expression showing a 65% response rate and 18.4 months median Progression-Free Survival (PFS).
- A Phase 2 study for evorpacept in HER2-positive breast cancer is expected to enroll the first patient this quarter (Q4 2025) and provide interim data in Q3 2026.
- The company's new program, ALX 2004, an EGFR-targeted ADC, is in a Phase 1 trial, with initial safety data anticipated in the first half of 2026.
- ALX Oncology expects its current cash position to last through Q1 2027.
Dec 3, 2025, 2:30 PM
ALX Oncology Provides Update on Evorpacept and ALX2004 Programs
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology is focused on two clinical programs: evorpacept, a differentiated CD47 inhibitor, and ALX2004, a novel EGFR targeted ADC.
- For evorpacept, interim data from the Phase 2 breast cancer study is expected in Q3 2026, with the company aiming for a 35% or more response rate in double-positive patients.
- The ALX2004 EGFR targeted ADC program dosed its first patient in August 2025, cleared the first dose level without dose-limiting toxicities (DLTs), and anticipates safety data in H1 2026.
- The company's cash runway is projected to extend into early Q1 2027.
Nov 19, 2025, 11:30 AM
Quarterly earnings call transcripts for ALX ONCOLOGY HOLDINGS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more